Question 1

What is the difference between Victoza and Zepbound?

Accepted Answer

Victoza and Zepbound are both injectable incretin therapies but treat different conditions through different mechanisms. Victoza is liraglutide, a GLP-1 receptor agonist injected daily at doses up to 1.8 mg, FDA-approved in 2010 for type 2 diabetes and in 2017 for cardiovascular risk reduction in patients with T2DM and established CVD. Zepbound is tirzepatide, a dual GIP and GLP-1 receptor agonist injected weekly at doses from 2.5 mg to 15 mg, FDA-approved in 2023 for chronic weight management and in 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity. The dosing, mechanisms, manufacturers, and labels are entirely separate.

Question 2

Are Victoza and Zepbound used for the same condition?

Accepted Answer

No. Victoza targets type 2 diabetes and cardiovascular risk in that population. Zepbound targets chronic weight management and obstructive sleep apnea in patients with obesity. There is no overlap in their FDA-approved uses. For a more relevant comparison: the diabetes form of tirzepatide is Mounjaro (same molecule as Zepbound, different label); the obesity form of liraglutide is Saxenda at the higher 3.0 mg daily dose. Patients comparing Victoza and Zepbound are typically researching the GLP-1 landscape rather than choosing between these two specifically.

Question 3

Which causes more weight loss?

Accepted Answer

Zepbound produces dramatically more weight loss than Victoza, in part because it is FDA-approved and dose-engineered for that purpose. In SURMOUNT-1, adults on Zepbound 15 mg weekly lost an average of 22.5 percent of baseline body weight (25.3 kg absolute) over 72 weeks, with about 63 percent achieving at least 20 percent loss. Victoza 1.8 mg daily in LEADER produced about 2.8 kg of weight loss (approximately 3.2 percent) over 3.8 years as a secondary effect in a diabetes population. The labeled liraglutide weight-management product is Saxenda at 3.0 mg daily, which produces roughly 8 percent mean loss in SCALE — still well below Zepbound.

Question 4

Could a patient be on both Victoza and Zepbound?

Accepted Answer

Combining two incretin therapies (a GLP-1 agonist and a dual GIP/GLP-1 agonist) is generally not recommended. The Zepbound prescribing information specifically warns against concurrent use with other GLP-1 receptor agonists due to additive gastrointestinal burden and overlapping mechanisms without established benefit. For a patient with both type 2 diabetes and obesity, the cleaner path is a dual-indication tirzepatide pair (Mounjaro for diabetes plus Zepbound for weight, both labeled), or a semaglutide pair (Ozempic plus Wegovy). Running Victoza and Zepbound in parallel would also create insurance coverage problems.

Question 5

Which has fewer side effects, Victoza or Zepbound?

Accepted Answer

The side-effect profiles differ in pattern and intensity. Victoza 1.8 mg daily produces nausea around 28 percent, diarrhea 17 percent, and vomiting 11 percent — daily peaks contribute to consistent gastrointestinal load. Zepbound at maintenance doses (10 to 15 mg weekly) shows nausea 24 to 33 percent, diarrhea 18 to 25 percent, and vomiting 10 to 18 percent. Zepbound also reports hair loss in about 5 percent of users (versus 1 percent on placebo) tied to rapid weight loss, and gallbladder events at 1.6 percent. Both carry the class thyroid C-cell tumor boxed warning. Both have low intrinsic hypoglycemia risk but elevated risk when combined with insulin or sulfonylureas.

Question 6

Is Victoza or Zepbound better covered by insurance?

Accepted Answer

Victoza coverage for type 2 diabetes is broad on commercial plans and Medicare Part D, often at low copay tiers — and generic liraglutide that launched in 2024 has further reduced costs. Zepbound coverage is more restrictive. Many commercial plans exclude weight-management medications entirely; the December 2024 OSA indication added a coverage pathway for patients with moderate-to-severe sleep apnea. Medicare Part D does not cover Zepbound for weight loss alone under federal law. Zepbound is also available through Eli Lilly's direct pharmacy in single-dose vial form at reduced self-pay pricing for patients without coverage.

Question 7

Does Victoza protect against cardiovascular events the way Zepbound might?

Accepted Answer

Victoza has documented cardiovascular benefit in patients with type 2 diabetes and established CVD — LEADER showed a 13 percent reduction in major adverse cardiovascular events over a median 3.8 years, which led to an FDA-labeled CV indication in 2017. Zepbound has not yet established a labeled cardiovascular benefit; the SURMOUNT-MMO cardiovascular outcomes trial in obesity and the SURPASS-CVOT trial in diabetes (using the same tirzepatide molecule under the Mounjaro label) are the relevant studies in progress. The Wegovy SELECT trial did demonstrate CV benefit for semaglutide in obesity. For now, Victoza is the only one of these two with a labeled CV indication.

Question 8

Can patients with diabetes plus obesity use Zepbound off-label?

Accepted Answer

Zepbound itself is FDA-approved for chronic weight management and obstructive sleep apnea, not type 2 diabetes — but the same tirzepatide molecule is approved for diabetes under the Mounjaro label. Most prescribers will choose Mounjaro for a patient whose primary issue is diabetes (with weight as secondary) and Zepbound for a patient whose primary issue is obesity (with diabetes as comorbidity), or use both products under their respective labels for patients meeting both label criteria. Off-label use of Zepbound for diabetes alone is rare because Mounjaro covers that indication directly; insurance approval is also more straightforward when the label matches the diagnosis.

Feature	Victoza(liraglutide)	Zepbound(tirzepatide)
Active Ingredient	liraglutide	tirzepatide
Drug Class	GLP-1 receptor agonist	Dual GIP and GLP-1 receptor agonist
Manufacturer	Novo Nordisk	Eli Lilly
FDA Approved	2010-01-25	2023-11-08
Approved Indications	Type 2 diabetes mellitus (adjunct to diet and exercise) Reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease Type 2 diabetes in patients aged 10+ years	Chronic weight management in adults with BMI ≥30 or ≥27 with at least one weight-related comorbidity (adjunct to diet and exercise) Treatment of moderate-to-severe obstructive sleep apnea in adults with obesity (December 20, 2024)
Route	subcutaneous injection	subcutaneous injection
Frequency	Once daily	Once weekly
Starting Dose	0.6 mg daily	2.5 mg weekly
Maintenance Dose	1.2 mg or 1.8 mg daily	5 mg, 10 mg, or 15 mg weekly
Max Dose	1.8 mg daily	15 mg weekly
Weight Loss (%)	3.2%	22.5%
A1C Reduction	1.1%	N/A (not indicated for diabetes)
Key Trial	LEADER (188 weeks)	SURMOUNT-1 / SURMOUNT-5 (head-to-head vs semaglutide) (72 weeks)
List Price	$950-$1,100/month	$1,060-$1,176/month
With Insurance	$25-$150/month (varies by plan)	$25-$250/month (varies; weight-loss coverage is limited)
Savings Card	$25/month (Novo Nordisk savings card, commercially insured)	$25/month (Lilly savings card, commercially insured)

Side Effect	Victoza	Zepbound
Nausea	28%	24-33%
Diarrhea	17%	18-25%
Vomiting	11%	10-18%
Headache	9%	Not reported
Decreased appetite	9%	Not reported
Dyspepsia	7%	7-10%
Constipation	6%	13-17%
Pancreatitis (rare)	<1%	<1%
Abdominal pain	Not reported	10-14%
Injection site reaction	Not reported	3-7%
Hair loss	Not reported	5-6%
Gallbladder events	Not reported	1.6%

Victoza vs Zepbound

Summary

Different FDA-Approved Indications

Mechanism, Dose, and Administration

Efficacy in Their Respective Labeled Conditions

Coverage and Practical Considerations

Victoza vs Zepbound: Full Comparison

Side Effects: Victoza vs Zepbound

Related Comparisons

Frequently Asked Questions

Sources & References

FDA & Regulatory

Clinical Trial Records

Peer-Reviewed Literature

Safety Communications

Manufacturer Information

Reference Entries

Additional References